article thumbnail

Why demand is rising for secure and climate-controlled gene therapy services

Pharmaceutical Technology

Although only a small number of gene therapies have reached the market thus far, the industry is poised to grow quickly over the next few years. According to GlobalData’s clinical trials database, there are currently 1,231 planned and ongoing trials for gene therapies and gene-modified cell therapies alone.

article thumbnail

Finding a cure: How cell and gene therapies could revolutionise medicine

Pharmaceutical Technology

Cell and gene therapies are predicted to be the future of medical treatment by providing the body with the means to repair itself and recover from a range of serious conditions and severe diseases. Often, cell and gene therapies are spoken of as miracle treatments, yet this progress has hardly occurred overnight.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bayer Continues Eying Potential Partnerships in Cell and Gene Therapy Space

BioSpace

In an interview with BioSpace, Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, outlined Bayer’s thought process for opening its purse strings and diving into the deep end of the cell and gene therapy space.

article thumbnail

CAMP4’s funding influx paves the way for tapping regulatory RNA to treat urea cycle disorders

Pharmaceutical Technology

Ultragenyx uses adeno-associated virus 8 (AAV8) gene therapy to induce stable OTC gene expression. This treatment activates the OTC gene so that ammonia can be removed from the blood. This gene therapy will give the instructions to produce the enzyme arginine so that it can be hydrolysed to ornithine.

RNA 245
article thumbnail

Novartis to showcase next-gen manufacturing solutions at BIO 2024

BioPharma Reporter

Before the industry is set to arrive in San Diego for Bio International 2024, we spoke with Dr. Harald Oberegger, global head business development at Novartis Contract Manufacturing.

article thumbnail

EdiGene Expands Management Team by Appointment of Head of US Subsidiary Dr. Bo Zhang and Head of Business Development Dr. Kehua Fan

The Pharma Data

.–( BUSINESS WIRE )– EdiGene, Inc. which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. Both will report to Dr. Dong Wei, CEO of EdiGene.

article thumbnail

Changing Faces: pharma supplier, DTx, and non-profit hires from November 2022

pharmaphorum

Maishman brings a wealth of experience to the cell and gene therapy-focused company, having worked at GlaxoSmithKline, Pfizer, Valneva, Alexion, and Recipharm in various leadership roles. Pete previously worked with Amazon, Babylon Health, and Sony. Other pharma supplier hires.